A study of the effect of conversion to enteric-coated mycophenolate sodium on quality of life in patients with gastrointestinal symptoms related to mycophenolate mofetil therapy after renal transplantation

Trial Profile

A study of the effect of conversion to enteric-coated mycophenolate sodium on quality of life in patients with gastrointestinal symptoms related to mycophenolate mofetil therapy after renal transplantation

Completed
Phase of Trial: Phase IV

Latest Information Update: 27 Jul 2011

At a glance

  • Drugs Mycophenolate mofetil; Mycophenolate sodium
  • Indications Renal transplant rejection
  • Focus Adverse reactions
  • Sponsors Novartis
  • Most Recent Events

    • 27 Jul 2011 New trial record
    • 14 Jul 2011 Results published in the Transplantation.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top